Sensorion Presents SENS-601 Gene Therapy Research at ESGCT Congress
Sensorion presented research on its SENS-601 gene therapy for deafness at the ESGCT congress.
Related stories
Nikkei Index Falls 3%
M impact | EQUITY | Oct 30, 2026, 01:54 AM UTC
Chongqing Gas Q3 Net Profit Falls 88.27% Year Over Year
Chongqing Gas reported an 88.27% year-over-year decline in net profit for the first three quarters.
M impact | EQUITY | Oct 30, 2026, 01:54 AM UTC
AIA Shares Hit 4-week High
AIA shares increased to 74.10 HKD, the highest since September 2026. Over the past 4 weeks, AIA Group gained 6.58%, and in the last 12 months, it decreased 2.25%.
L impact | EQUITY | Oct 30, 2026, 01:53 AM UTC
Japan's Nikkei average falls 3%
M impact | EQUITY | Oct 30, 2026, 01:53 AM UTC
Japan’s Nikkei average down 3%
M impact | EQUITY | Oct 30, 2026, 01:53 AM UTC
Reddit Shares Plunge 18% After Revenue Outlook Misses Expectations
Reddit shares fell about 18% in after-hours trading in New York after the company said it would limit unregistered users’ access to its platform and issued a revenue outlook below
M impact | EQUITY | Oct 30, 2026, 01:51 AM UTC